Literature DB >> 24566499

Diagnosis and Treatment of Venous Malformations. Consensus Document of the International Union of Phlebology (IUP): updated 2013.

B B Lee, I Baumgartner, P Berlien, G Bianchini, P Burrows, P Gloviczki, Y Huang, J Laredo, D A Loose, J Markovic, R Mattassi, K Parsi, E Rabe, M Rosenblatt, C Shortell, F Stillo, M Vaghi, L Villavicencio, P Zamboni.   

Abstract

Venous malformations (VMs) are the most common vascular developmental anomalies (birth defects) . These defects are caused by developmental arrest of the venous system during various stages of embryogenesis. VMs remain a difficult diagnostic and therapeutic challenge due to the wide range of clinical presentations, unpredictable clinical course, erratic response to the treatment with high recurrence/ persistence rates, high morbidity following non-specific conventional treatment, and confusing terminology. The Consensus Panel reviewed the recent scientific literature up to the year 2013 to update a previous IUP Consensus (2009) on the same subject. ISSVA Classification with special merits for the differentiation between the congenital vascular malformation (CVM) and vascular tumors was reinforced with an additional review on syndrome-based classification. A "modified" Hamburg classification was adopted to emphasize the importance of extratruncular vs. truncular sub-types of VMs. This incorporated the embryological ongm, morphological differences, unique characteristics, prognosis and recurrence rates of VMs based on this embryological classification. The definition and classification of VMs were strengthened with the addition of angiographic data that determines the hemodynamic characteristics, the anatomical pattern of draining veins and hence the risk of complication following sclerotherapy. The hemolymphatic malformations, a combined condition incorporating LMs and other CVMs, were illustrated as a separate topic to differentiate from isolated VMs and to rectify the existing confusion with name-based eponyms such as Klippei-Trenaunay syndrome. Contemporary concepts on VMs were updated with new data including genetic findings linked to the etiology of CVMs and chronic cerebrospinal venous insufficiency. Besides, newly established information on coagulopathy including the role of D-Dimer was thoroughly reviewed to provide guidelines on investigations and anticoagulation therapy in the management of VMs. Congenital vascular bone syndrome resulting in angio-osteo-hyper/hypotrophy and (lateral) marginal vein was separately reviewed. Background data on arterio-venous malformations was included to differentiate this anomaly from syndromebased VMs. For the treatment, a new section on laser therapy and also a practical guideline for follow up assessment were added to strengthen the management principle of the multidisciplinary approach. All other therapeutic modalities were thoroughly updated to accommodate a changing concept through the years.

Entities:  

Mesh:

Year:  2015        PMID: 24566499

Source DB:  PubMed          Journal:  Int Angiol        ISSN: 0392-9590            Impact factor:   2.789


  28 in total

1.  [Vascular anomalies. Part II: vascular malformations].

Authors:  S Mylonas; S Brunkwall; J Brunkwall
Journal:  Chirurg       Date:  2018-04       Impact factor: 0.955

Review 2.  Intraosseous venous malformation of the zygomatico-orbital complex. Case report and literature review with focus on confusions in vascular lesion terms.

Authors:  Zoltán Fábián; György Szabó; Cecilia Petrovan; Karin Ursula Horváth; Botond Babicsák; Kálmán Hüttl; Zsolt Németh; Sándor Bogdán
Journal:  Oral Maxillofac Surg       Date:  2018-04-13

3.  [Vascular anomalies. Part I: vascular tumors].

Authors:  S Mylonas; S Brunkwall; J Brunkwall
Journal:  Chirurg       Date:  2018-03       Impact factor: 0.955

Review 4.  Evaluation and Management of Chronic Venous Disease Using the Foundation of CEAP.

Authors:  Teresa L Carman; Ali Al-Omari
Journal:  Curr Cardiol Rep       Date:  2019-08-30       Impact factor: 2.931

Review 5.  Role of interventional radiology in the management of musculoskeletal soft-tissue lesions.

Authors:  Francesco Arrigoni; Federico Bruno; Luigi Zugaro; Alessandra Splendiani; Ernesto Di Cesare; Antonio Barile; Carlo Masciocchi
Journal:  Radiol Med       Date:  2018-04-23       Impact factor: 3.469

6.  Effects of Venous Angioplasty on Cerebral Lesions in Multiple Sclerosis: Expanded Analysis of the Brave Dreams Double-Blind, Sham-Controlled Randomized Trial.

Authors:  Paolo Zamboni; Roberto Galeotti; Fabrizio Salvi; Alessia Giaquinta; Carlo Setacci; Salvatore Alborino; Giuseppe Guzzardi; Salvatore J Sclafani; Elisa Maietti; Pierfrancesco Veroux
Journal:  J Endovasc Ther       Date:  2019-11-17       Impact factor: 3.487

7.  Ethanolgel sclerotherapy of venous malformations improves health-related quality-of-life in adults and children - results of a prospective study.

Authors:  Walter A Wohlgemuth; Rene Müller-Wille; Veronika Teusch; Simone Hammer; Moritz Wildgruber; Wibke Uller
Journal:  Eur Radiol       Date:  2016-10-04       Impact factor: 5.315

8.  Clinical outcome and predictors of treatment response in foam sodium tetradecyl sulfate sclerotherapy of venous malformations.

Authors:  Hong Suk Park; Young Soo Do; Kwang Bo Park; Keon-Ha Kim; Sook Young Woo; Sin-Ho Jung; Dong-Ik Kim; Young Wook Kim; Dongho Hyun; Sung Ki Cho; In Wook Choo
Journal:  Eur Radiol       Date:  2015-08-26       Impact factor: 5.315

9.  DSA-guided percutaneous sclerotherapy for children with oropharyngeal low-flow venous malformation.

Authors:  Dan Song; Lei Guo; Hui Sheng; Jing Li; Liang Wang; Changhua Wu; Changfeng Wang; Yanli Niu; Qingshi Zeng
Journal:  Exp Ther Med       Date:  2020-03-06       Impact factor: 2.447

10.  Treatment of Low-Flow Vascular Malformations of the Extremities Using MR-Guided High Intensity Focused Ultrasound: Preliminary Experience.

Authors:  Pejman Ghanouni; Sirish Kishore; Matthew P Lungren; Rachelle Bitton; Lauren Chan; Raffi Avedian; Alberto Bazzocchi; Kim Butts Pauly; Alessandro Napoli; David M Hovsepian
Journal:  J Vasc Interv Radiol       Date:  2017-12       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.